Attovia Therapeutics, Inc.
ATTOHealthcare|Biotechnology|US
$15.27
+0.27 (+1.80%)
DCF Value
$0.98
Tangible Book / Share
$2.47
Cash / Share
$2.52
About
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Stock Price
-30.3%(1Y)
1M
-6.4%
3M
-24.3%
6M
-30.3%
YTD
-30.3%
1Y
-30.3%
3Y
-30.3%
5Y
-30.3%
Pipeline Summary
4 total trials3
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Not Yet Recruiting: 2Completed: 2
Key Facts
Market Cap$697.1M
Employees44
CEOTao Fu
IPO DateAug 5, 2026
Beta0.00
52-Week Range$12.94 – $28
Avg Volume418,965
ExchangeNASDAQ
Websiteattovia.com
Ownership
Float62.3%
Shares Outstanding45.7M
Recent Insider Trades
Fu TaoAWARD
Aug 4, 2026538,300 shares @ $17.00
Chan StevenAWARD
Aug 4, 2026140,000 shares @ $17.00
Fu TaoOTHER
Aug 4, 20260 shares
Fu TaoOTHER
Aug 4, 20260 shares
Fu TaoOTHER
Aug 4, 20260 shares
Peers
Recent News
Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials
Nov 6, 2026 · marketbeat.com
Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic Dermatitis
Nov 5, 2026 · globenewswire.com
Attovia Therapeutics to Participate in Upcoming Investor Conferences
Oct 27, 2026 · globenewswire.com
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
Sep 28, 2026 · globenewswire.com
Attovia Therapeutics, Inc. (ATTO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sep 16, 2026 · seekingalpha.com
Data last updated: Nov 9, 2026, 03:57 AM